Literature DB >> 26604113

Treatment of Osteoid Osteomas Using a Navigational Bipolar Radiofrequency Ablation System.

Adam N Wallace1, Anderanik Tomasian2, Randy O Chang3, Jack W Jennings2.   

Abstract

BACKGROUND: Percutaneous CT-guided radiofrequency ablation is a safe and effective minimally invasive treatment for osteoid osteomas. This technical case series describes the use of a recently introduced ablation system with a probe that can be curved in multiple directions, embedded thermocouples for real-time monitoring of the ablation volume, and a bipolar design that obviates the need for a grounding pad.
METHODS: Medical records of all patients who underwent radiofrequency ablation of an osteoid osteoma with the STAR Tumor Ablation System (DFINE; San Jose, CA) were reviewed. The location of each osteoid osteoma, nidus volume, and procedural details were recorded. Treatment efficacy and long-term complications were assessed at clinical follow-up.
RESULTS: During the study period, 18 osteoid osteomas were radiofrequency ablated with the multidirectional bipolar system. Lesion locations included the femur (50%; 9/18), tibia (22%; 4/18), cervical spine (11%; 2/18), calcaneus (5.5%; 1/18), iliac bone (5.5%; 1/18), and fibula (5.5%; 1/18). The median nidus volume of these cases was 0.33 mL (range 0.12-2.0 mL). All tumors were accessed via a single osseous channel. Median cumulative ablation time was 5 min and 0 s (range 1 min and 32 s-8 min and 50 s). All patients with clinical follow-up reported complete symptom resolution. No complications occurred.
CONCLUSION: Safe and effective CT-guided radiofrequency ablation of osteoid osteomas can be performed in a variety of locations using a multidirectional bipolar system.

Entities:  

Keywords:  CT; Osteoid osteoma; Radiofrequency ablation

Mesh:

Year:  2015        PMID: 26604113     DOI: 10.1007/s00270-015-1243-8

Source DB:  PubMed          Journal:  Cardiovasc Intervent Radiol        ISSN: 0174-1551            Impact factor:   2.740


  8 in total

Review 1.  Benign Spine Lesions: Advances in Techniques for Minimally Invasive Percutaneous Treatment.

Authors:  A Tomasian; A N Wallace; J W Jennings
Journal:  AJNR Am J Neuroradiol       Date:  2017-02-09       Impact factor: 3.825

2.  Percutaneous Radiofrequency Ablation of Spinal Osteoid Osteomas Using a Targeted Navigational Bipolar Electrode System.

Authors:  A Tomasian; J W Jennings
Journal:  AJNR Am J Neuroradiol       Date:  2018-10-25       Impact factor: 3.825

3.  Percutaneous CT-Guided Microwave Ablation Combined with Vertebral Augmentation for Treatment of Painful Spinal Metastases.

Authors:  L Chen; G Hou; K Zhang; Z Li; S Yang; Y Qiu; Q Yuan; D Hou; X Ye
Journal:  AJNR Am J Neuroradiol       Date:  2022-02-03       Impact factor: 3.825

Review 4.  Primary tumours of the calcaneus.

Authors:  Litao Yan; Junwei Zong; Jin Chu; Wendong Wang; Mingshu Li; Xianfeng Wang; Mingzhi Song; Shouyu Wang
Journal:  Oncol Lett       Date:  2018-04-13       Impact factor: 2.967

5.  Computed tomography-guided percutaneous radiofrequency and laser ablation for the treatment of osteoid osteoma - long-term follow-up from 5 to 10 years.

Authors:  Tomasz Lorenc; Hanna Kocoń; Marek Gołębiowski
Journal:  Pol J Radiol       Date:  2021-01-12

6.  Safety and Feasibility of Steerable Radiofrequency Ablation in Combination with Cementoplasty for the Treatment of Large Extraspinal Bone Metastases.

Authors:  Claudio Pusceddu; Davide De Francesco; Nicola Ballicu; Domiziana Santucci; Salvatore Marsico; Massimo Venturini; Davide Fior; Lorenzo Paolo Moramarco; Eliodoro Faiella
Journal:  Curr Oncol       Date:  2022-08-20       Impact factor: 3.109

7.  Osteoid osteoma: Contemporary management.

Authors:  Shahryar Noordin; Salim Allana; Kiran Hilal; Naila Nadeem; Riaz Lakdawala; Anum Sadruddin; Nasir Uddin
Journal:  Orthop Rev (Pavia)       Date:  2018-09-25

Review 8.  Management of Osteoblastoma and Giant Osteoid Osteoma with Percutaneous Thermoablation Techniques.

Authors:  Antonio Izzo; Luigi Zugaro; Eva Fascetti; Federico Bruno; Carmine Zoccali; Francesco Arrigoni
Journal:  J Clin Med       Date:  2021-12-07       Impact factor: 4.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.